DOV Pharmaceutical DOVP
-
Dropping Coverage of DOV Pharma
We're dropping coverage of DOV Pharmaceutical DOVP in order to focus on other investment opportunities in the health-care sector. DOV continues to teeter on the edge of bankruptcy …
-
Neurocrine, DOV under Review
… 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon sales, we are placing that firm under review as well. The event moves …
-
DOV Scraps Merck Agreement
On Wednesday, DOV Pharmaceutical DOVP terminated its development and marketing agreement with Merck MRK, which covered compound DOV 216,303 for depression. DOV …
-
Neurocrine's Delay Will Hurt DOV
… estimate by a few dollars after revisiting our assumptions. The event may also be the nail in the coffin for DOV Pharmaceutical DOVP , a company on the verge of bankruptcy that depends on royalties from indiplon sales; we already value DOV at …
-
DOV Delisted, Possibly Bankrupt
DOV Pharmaceutical DOVP may file for bankruptcy following Nasdaq's decision to delist its stock. Our fair value estimate remains $0. Thursday's …
-
DOV Shifts Strategy
DOV Pharmaceutical DOVP made two announcements Tuesday that, while important, do not affect our fair value estimate. First, the company plans to shift …
-
DOV Pharma May Be Delisted
DOV Pharmaceutical DOVP received a notice from the Nasdaq on Monday that is likely to lead to the delisting of the stock. The event doesn't affect our …
-
Neurocrine's Indiplon Delayed
Neurocrine Biosciences NBIX and DOV Pharmaceutical DOVP were disappointed Thursday when Pfizer PFE walked away from its agreement to market indiplon for insomnia. We'll investigate …
-
DOV Shares Bicifadine Analysis
DOV Pharmaceutical DOVP shared its analysis of the failed bicifadine trial on Monday. We're maintaining our fair value estimate; we remain pessimistic …
-
Neurocrine's Indiplon Delayed
… indiplon's sales potential in the absence of a 2006 launch. We're also placing our fair value estimate for DOV Pharmaceutical DOVP , a company entitled to a 3.5% royalty on indiplon sales, under review. Now that DOV's bicifadine compound …